Revolution Medicines, Inc.
NASDAQ:RVMD
59.1 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 11.58 | 35.38 | 29.39 | 42.983 | 50.041 | 20.165 | 0 |
| Cost of Revenue
| 9.309 | 9.656 | 7.332 | 132.252 | 91.755 | 1.764 | 1.188 |
| Gross Profit
| 2.271 | 25.724 | 22.058 | -89.269 | -41.714 | 18.401 | -1.188 |
| Gross Profit Ratio
| 0.196 | 0.727 | 0.751 | -2.077 | -0.834 | 0.913 | 0 |
| Reseach & Development Expenses
| 417.034 | 253.073 | 186.948 | 132.252 | 91.755 | 51.084 | 26.586 |
| General & Administrative Expenses
| 75.621 | 40.586 | 30.45 | 21.428 | 12.406 | 9.41 | 4.543 |
| Selling & Marketing Expenses
| -3.199 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 72.422 | 40.586 | 30.45 | 21.428 | 12.406 | 9.41 | 4.543 |
| Other Expenses
| 0.115 | 0 | 0 | 0 | 0 | -2.121 | 0 |
| Operating Expenses
| 489.456 | 293.659 | 217.398 | 153.68 | 104.161 | 60.494 | 31.129 |
| Operating Income
| -487.185 | -258.279 | -188.008 | -110.697 | -54.12 | -40.329 | -31.129 |
| Operating Income Ratio
| -42.071 | -7.3 | -6.397 | -2.575 | -1.082 | -2 | 0 |
| Total Other Income Expenses Net
| 47.294 | 9.154 | 0.917 | 2.167 | 2.083 | -2.121 | 0.002 |
| Income Before Tax
| -439.891 | -249.125 | -187.091 | -108.53 | -52.037 | -41.789 | -31.127 |
| Income Before Tax Ratio
| -37.987 | -7.041 | -6.366 | -2.525 | -1.04 | -2.072 | 0 |
| Income Tax Expense
| -3.524 | -0.42 | -7.32 | -0.371 | -4.373 | -1.344 | 0.105 |
| Net Income
| -436.367 | -248.705 | -179.771 | -108.159 | -47.664 | -41.789 | -31.127 |
| Net Income Ratio
| -37.683 | -7.03 | -6.117 | -2.516 | -0.952 | -2.072 | 0 |
| EPS
| -3.86 | -3.08 | -2.47 | -1.62 | -0.81 | -1.15 | -0.85 |
| EPS Diluted
| -3.86 | -3.08 | -2.47 | -1.62 | -0.81 | -1.15 | -0.85 |
| EBITDA
| -477.876 | -249.125 | -187.079 | -108.459 | -48.589 | -39.909 | -29.836 |
| EBITDA Ratio
| -41.267 | -7.041 | -6.365 | -2.523 | -0.971 | -1.979 | 0 |